Comparison
10p13 P14 Deletion Syndrome Cn379618 vs 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Clinical comparison between 10p13 P14 Deletion Syndrome CN379618 and 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 for differential diagnosis and treatment planning.
10p13 P14 Deletion Syndrome Cn379618
A rare chromosomal disorder caused by deletion of genetic material on chromosome 10. It can affect development, facial features, and organ function. Management involves multidisciplinary care to address specific symptoms and provide developmental support.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
6 comparison axes
Onset
10p13 P14 Deletion Syndrome Cn379618
0-0
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
Onset patterns differ
Severity
10p13 P14 Deletion Syndrome Cn379618
severe
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
Different severity levels
Chronic
10p13 P14 Deletion Syndrome Cn379618
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
Differing course
Communicable
10p13 P14 Deletion Syndrome Cn379618
No
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
Different transmission
Body System
10p13 P14 Deletion Syndrome Cn379618
congenital
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Same/different system
Category
10p13 P14 Deletion Syndrome Cn379618
genetic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
Different category
Bottom line
10p13-p14-deletion-syndrome-CN379618 and 17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 10p13 P14 Deletion Syndrome Cn379618 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Discriminating power |
|---|---|---|---|
| Developmental pattern | May involve developmental differences from early life; exact features vary. | Pubertal development may be absent or incomplete; childhood development is not the defining feature. | Moderate |
| Genital and pubertal findings | Not established as a characteristic finding from the supplied description. | Ambiguous genitalia and lack of puberty are described. | High |
| Blood pressure | Hypertension is not established by the supplied description. | High blood pressure is described and needs clinical confirmation. | Moderate |
When to favor each condition
Choose 10p13 P14 Deletion Syndrome Cn379618 when
Congenital developmental concern with suspected chromosomal imbalance
The description centers on deletion of chromosome 10 material and developmental effects.
Moderate
Multiple congenital or organ findings without a primary endocrine pattern
Management is described as symptom-specific multidisciplinary support.
Low
Genetic evaluation suggests a 10p13-p14 deletion
Chromosomal testing, interpreted by a clinician, is the relevant diagnostic route.
High
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Ambiguous genitalia with absent or incomplete puberty
These findings are specifically described for the steroid disorder.
Moderate
Hypertension accompanying suspected disordered sex-steroid production
High blood pressure is part of the supplied clinical description.
Moderate
Endocrine testing suggests impaired 17-alpha-hydroxylase/17,20-lyase activity
The condition is defined by abnormal steroid hormone production, not a chromosomal deletion.
High
How key tests differ
| Test | 10p13 P14 Deletion Syndrome Cn379618 | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion involving 10p13-p14; result requires specialist interpretation. | Not expected to establish this enzyme deficiency. | A chromosomal result supports the left condition only when clinically correlated. |
| Steroid hormone profile | No characteristic pattern is established here. | May show disordered steroid production; exact cutoffs are not supplied. | Abnormal results are findings, not a diagnosis by themselves. |
| Blood pressure assessment | No specific abnormality is established by the source. | Hypertension may be present and should be clinically evaluated. | Blood pressure supports endocrine assessment but does not prove the diagnosis. |
Prognosis comparison
10p13 P14 Deletion Syndrome Cn379618
- Outcome
- Chronic course is described, but individual outcome is not established.
- Factors
- Affected development, organ involvement, and available supportive care may influence needs.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine condition; lifelong hormone replacement is described.
- Factors
- Blood pressure, pubertal development, and treatment response require clinician monitoring.
Time frame: Both are described as chronic; precise timelines are not established.
Diagnosis confirmation, symptom pattern, and specialist follow-up are key.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental and organ effects | Development, facial features, and organ function may be affected. Not the primary described complication. Specific complications vary and are not fully established here. |
| Sex development and puberty | Not established from the supplied data. Ambiguous genitalia and lack of puberty are described. Specialist assessment is needed; do not infer severity from this comparison. |
| Hypertension-related risk | Not established by the source description. High blood pressure is described and may need long-term monitoring. Outcomes and exact risks are not provided. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other affects steroid hormone production. Testing must be interpreted clinically.
- HighCare needs
Deletion-related care is multidisciplinary and symptom-based; the enzyme deficiency is described as needing lifelong hormone replacement.
- MediumWhat is not known
Prevalence, exact laboratory cutoffs, mortality, and treatment doses are not established in this comparison.